Description: ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Home Page: www.erytech.com
60 Avenue Rockefeller
Lyon,
69008
France
Phone:
33 4 78 74 44 38
Officers
| Name | Title |
|---|---|
| Mr. Gil Beyen BVBA | CEO & Director |
| Mr. Eric Soyer Ph.D. | Deputy GM, CFO & COO |
| Dr. Jérôme Bailly Pharm.D. | Deputy GM of Operations, Chief Quality Officer & Qualified Person |
| Naomi Eichenbaum | Director Investor Relations |
| Mr. Brian Schwab | Chief Legal Officer & Gen. Counsel |
| Ms. Anne-Cécile Fumey | HR Director |
| Dr. Iman El-Hariry M.D., Ph.D. | Chief Medical Officer |
| Dr. Philip L. Lorenzi | Consultant & Member of Scientific Board |
| Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board |
| Dr. Bridget Bax | Consultant & Member of Scientific Board |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7009 |
| Price-to-Sales TTM: | 8.0042 |
| IPO Date: | 2017-11-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 181 |